Literatur
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD et al (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology 60(2):715–735
Vince AJ, Burridge SM (1980) Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol 13(2):177–191
Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM (1974) Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut 15(12):999–1004
Kiafar C, Gilani N (2008) Hepatic hydrothorax: current concepts of pathophysiology and treatment options. Ann Hepatol 7(4):313–320
Heinemann H (1960) Respiration and circulation in patients with portal cirrhosis of the liver. Circulation 22(1):154–159
Lustik SJ, Chhibber AK, Kolano JW, Hilmi IA, Henson LC, Morris MC et al (1997) The hyperventilation of cirrhosis: progesterone and estradiol effects. Hepatology 25(1):55–58
McAuliffe JJ, Lind LJ, Leith DE, Fencl V (1986) Hypoproteinemic alkalosis. Am J Med 81(1):86–90
Funk G, Doberer D, Fuhrmann V, Holzinger U, Kitzberger R, Kneidinger N et al (2006) The acidifying effect of lactate is neutralized by the alkalinizing effect of hypoalbuminemia in non-paracetamol-induced acute liver failure. J Hepatol 45(3):387–392
Drolz A, Horvatits T, Roedl K, Rutter K, Brunner R, Zauner C et al (2018) Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. Ann Intensive Care 8(1):1–12
Nolte W, Wiltfang J, Schindler C, Münke H, Unterberg K, Zumhasch U et al (1998) Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 28(5):1215–1225
Moroni F, Carpenedo R, Venturini I, Baraldi M, Zeneroli ML (1998) Oxindole in pathogenesis of hepatic encephalopathy. Lancet 351(9119:1861):78807–78803
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A.-R. Kabbani erklärt, dass er Verbindungen zu Merck/MSD (Reisekostenerstattung) hat. T.L. Tergast gibt an, dass kein Interessenkonflikt besteht. M.P. Manns erklärt, dass er Verbindungen (Principal Investigator/Studien/Vortrags-und Beraterhonorare) zu AbbVie, Bristol Myers Squibb, CureVac, Enyo Pharma, Falk Pharma, Janssen, Merck/MSD, Gilead Sciences, Medgenics, Novartis, Roche, PregLem, Gedeon Richter und Allergan hat; zudem werden Reisekosten von AbbVie, Bristol Myers Squibb, Janssen, Merck/MSD, Falk Pharma, Gilead Sciences, Novartis und Roche erstattet. B. Maasoumy hat Vortrags- und/oder Beraterhonorare von AbbVie, Bristol-Myers Squibb, Janssen, Merck/MSD, Abbott, Fujirebio, Roche; Studienunterstützung von Abbott, Fujirebio und Roche wie auch Reisekostenerstattungen von Gilead Science, Bristol-Myers Squibb, AbbVie, Merck/MSD und Janssen erhalten.
Rights and permissions
About this article
Cite this article
Kabbani, AR., Tergast, T.L., Manns, M.P. et al. Alkalose, Albumin, Ammoniak und die hepatische Enzephalopathie. Med Klin Intensivmed Notfmed 116, 358–359 (2021). https://doi.org/10.1007/s00063-021-00812-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00063-021-00812-5